DOCKETS ENTERED on 12/19/00

Food and Drug Administration, Dockets Management Branch, 5630 Fishers Lane - Room 1061- HFA-305, Rockville, MD, 20852; 301-827-6860; Fax 301-827-6870 [E-mail Us]

DOCKETS ENTERED on December 19, 2000

TABLE OF CONTENTS

Hyper links are part of the Docket title - not all dockets/documents are linked.

NOTE: Documents received by the Dockets Management Branch "MAY" be posted on the Internet. PLEASE DO NOT include personal identifying information, i.e. date of birth, social security number, etc., in your correspondence.

[FDA DOCKETS PAGE] [FDA HOME PAGE] [ ITEM CODES ]

91N-0101 Antioxidant Vitamins & Cancer,Hlth. Claims & Label Statement *
97N-0314 Prescription Drug Products; Levothyroxine Sodium *
98P-1194 Withdrawal NADA Approval for Posilac - rBGH *
00N-1409 Revision of the Identification of the Ionotophoresis *
00P-1363 To Amend 21 CFR 165.110 to include a Standard of Identity *
00P-1675 Triage B-Type Natriuetic Peptide (BNP) Test (K003475) *
00P-1676 Electrode Lead Wires and Patient Cables *

91N-0101 Antioxidant Vitamins & Cancer,Hlth. Claims & Label Statement

SUP 5 Emord & Associates P C Vol#: 46

97N-0314 Prescription Drug Products; Levothyroxine Sodium

SUP 5 Knoll Pharmaceutical Company Vol#: 8

98P-1194 Withdrawal NADA Approval for Posilac - rBGH

C 804 Inez P Petersen Vol#: 36

C 805 Shauna Matetich Vol#: 36

C 806 Erin Hennemann Vol#: 36

99N-4282 Biotechnology in the Year 2000 and Beyond; Public Meetings

C 16826 Form letter count 11 Vol#: 486

00N-1409 Revision of the Identification of the Ionotophoresis

C 3 IOMED Inc Vol#: 1